Despite the broad implications of mTOR inhibitors in cancer therapy, the link between aberrant alternative splicing, a process that can influence cancer progression by generating diverse protein isoforms, and mTOR activation in HCC remains unexplored. This evidence concerns the gene MTOR and hepatocellular carcinoma.